59 results about "Serious infection" patented technology

A wound suture containing a solvatochromatic indicator that undergoes a color change in the presence of bacteria often associated with surgical site infection is provided. Such a color change provides a “real time” indication of the onset of infection, which may alert medical staff to apply an appropriate antimicrobial treatment (e.g., antibiotic) to the patient (e.g., human or animal) before a more serious infection occurs. The patient may also be able to accurately monitor the condition of a wound after discharge from the hospital. Further, the lack of a color change may provide the medical staff or patient with the assurance that the area is generally free of infection and clean.

The invention relates to a pharmaceutical composition for the treatment of abnormal energy metabolism, which is the pharmaceutical composition containing a) a medicine for promoting fatty acid oxidation or derivatives thereof and b) a medicine for promoting glucose oxidation or pharmaceutical salts thereof. The pharmaceutical composition can comprehensively balance the metabolisms of fatty acid and glucose, optimize the productivity of fatty acid and glucose, reduce the jeopardy of abnormal aggregation of acidic metabolites, including free fatty acid or lactic acid and the like on organism, treat mitochondrial dysfunction, improve the defect that trimetazidine and the like are likely to create the accumulation of free fatty acid owing to the suppression on the fatty acid oxidation, and can be used for the auxiliary treatment for a plurality of diseases featured by imbalanced energy metabolism, such as acute and chronic ischemia, traumas, serious infection, diabetes, tumors, etc.

The invention discloses a numerical control system capable of performing real-time control on renal pelvis pressure in ureteroscopy based on sheath-side optical fiber pressure sensor monitoring, whichcomprises an optical fiber pressure measuring system, an independent double-channel ureter leading-in sheath, a numerical control platform with a perfusion / attraction function and an intelligent terminal. In the system, a perfusion pump of a soft mirror connected with the numerical control platform enters a kidney through a main channel of the ureter leading-in sheath; an optical fiber pressure sensor enters a renal pelvis through a side channel to monitor the pressure of the renal pelvis, and both channels can be connected with negative pressure suction of the numerical control platform. According to the measured pressure feedback, the numerical control platform carries out data interaction with the intelligent terminal through wire / wireless; the intelligent terminal collects and analyzes the data in the operation, synchronously optimizes the working mode and can carry out later maintenance on the numerical control platform. The numerical control system has the advantages of real-time accurate pressure control, convenient adjustment and maintenance and the like, can effectively prevent complications such as kidney injury, serious infection and the like caused by high pressure inthe soft mirror operation, and improves the safety and the efficiency of the operation.

The invention relates to a novel broad-spectrum antifungal medicine compound, a broad-spectrum antifungal medicine composition, an application of the compound or the composition in the preparation of a broad-spectrum antifungal medicine, and an application of the compound or the composition in the preparation of a medicine used for treating severe invasive infection (comprising Candida krusei) caused by invasive aspergillosis and / or Fluconazole-resistant Monilia and / or severe infection caused by Scedosporium and fusarium. The novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition have extensive and strong antifungal activity and better dynamic property and safety. For deep mycotic infection, the novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition are better than the original voriconazole in the aspects of the antibiotic activity and the medicine resistance and is better than amphotericin B in the aspects of safety and effectiveness; and compared with the formerly applied voriconazole, Fluconazole, itraconazole and amphotericin B, the novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition have reinforced medicine effect, less adverse reaction and good safety.

The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical composition further including an excipient such as CVMC agent and is available in dry powder form for reconstitution before injection with a suitable solvent. The pharmaceutical compositions of this invention have been found normally to enhance resistance to precipitation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use. The invention further provides a process to manufacture these compositions and also a method of treating a subject having non-ocular infective conditions due to multi drug resistant bacterium.

A disposable safety syringe designed to prevent syringe handlers from being pricked by a needle by covering the needle with a needle shield, is provided. Special attention should be given to syringe needles because they are sharp enough to cause needle stick injuries before and after use. In particular, if a user is accidentally injured by a blood-stained needle, serious infections might be caused through the needle. Accordingly, the needle is covered with the needle shield after use. The needle shield is fitted over a syringe cylinder. A stopping tab prevents the needle shield from sliding off the cylinder. Inserting tabs are formed by cutting part of shield walls, and locking grooves are formed in the end of the inserting tabs. A fixing adapter has an engagement sill formed in the inner side thereof and a number of elastic fins in the outer side thereof, which is fitted on the locking tab of the needle fixer.

The strain relief device of this invention reduces injury and danger of serious infection at driveline skin exit sites caused by routine patient activities and accidental stresses on the drivelines of ventricle assist devices and similar externally powered implanted medical devices. The device comprises a sleeve that forms an adherent biological interface with the skin and compliant seals between the sleeve and driveline. The compliant seals mechanically decouple linear and rotary driveline motions from the sleeve, while isolating the patients internal tissue from the outside environment. This mechanical decoupling reduces stresses and injury to the adherent interface, thereby reducing the risk of bacterial entry and infection. The device may be inserted into the patient as part of the driveline assembly implantation procedure, and is positioned such that the skin contacts and adheres to the outer diameter of the sleeve. It may also be partially or completely replaced or retrofitted to previously implanted drivelines in a relatively simple procedure.

A disposable safety syringe designed to prevent syringe handlers from being pricked by a needle by covering the needle with a needle shield, is provided. Special attention should be given to syringe needles because they are sharp enough to cause needle stick injuries before and after use. In particular, if a user is accidentally injured by a blood-stained needle, serious infections might be caused through the needle. Accordingly, the needle is covered with the needle shield after use. The needle shield is fitted over a syringe cylinder. A stopping tab prevents the needle shield from sliding off the cylinder. Inserting tabs are formed by cutting part of shield walls, and locking grooves are formed in the end of the inserting tabs. A fixing adapter has an engagement sill formed in the inner side thereof and a number of elastic fins in the outer side thereof, which is fitted on the locking tab of the needle fixer.

The present invention relates to use an agent for the prevention and / or treatment of multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) comprising interleukin-22 (IL-22) as an effective ingredient. The present invention is applicable to prevention of or therapy for diseases from sepsis, septic shock, liver failure, to multiple organ dysfunction syndromes. More particularly, the present invention is useful for an emergency medical service, for treatment of injury caused by a traffic accident, burns, heat attacks, hypercytokinemia or severe infective diseases.

The invention relates to a traditional Chinese medicine preparation for preventing and treating bone marrow suppression after radiotherapy and chemotherapy. The traditional Chinese medicine preparation is prepared from, by weight, 10-20 parts of codonopsis pilosula, 15-60 parts of astragali radix, 15-20 parts of fructus ligustri lucidi, 10-20 parts of eclipta alba, 15-30 parts of caulis spatholobi, 10-30 parts of peanut coat, 10-20 parts of rhizoma polygonati, 6-10 parts of ginger and 10-15 parts of radix bupleuri. The traditional Chinese medicine preparation has the advantages of good curative effect and low cost, has the curative effect similar to GM-CsF on the aspect of leukopenia (including severe bone marrow suppression) after radiotherapy and chemotherapy, can improve the clinical symptoms, has no obvious side effect, and meanwhile can effectively improve blood platelet and hemoglobin values and effectively prevent adverse consequences, such as serious infection and fever caused by leukocyte decrease.

The present invention relates to use an agent for the prevention and / or treatment of multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) comprising interleukin-22 (IL-22) as an effective ingredient. The present invention is applicable to prevention of or therapy for diseases from sepsis, septic shock, liver failure, to multiple organ dysfunction syndromes. More particularly, the present invention is useful for an emergency medical service, for treatment of injury caused by a traffic accident, burns, heat attacks, hypercytokinemia or severe infective diseases.

The invention relates to the use of a certain subset of cytokine markers as prognostic variables of infection status in an individual, and especially as prognostic markers of a patients developing severe infection such as pneumonia, and respiratory tract infection following surgery. The subset of cytokine markers consists of the interleukin cytokines IL-2, IL-7, IL-23, IL-27, and IL-10, and Interferon-γ (INFγ) and Tissue Necrosis Factor-α (TNFα). The markers may be employed as individual prognostic variables of infection status, or they may be used in pairs or other combinations. Generally, the abundance of the markers is correlated with infection status by means of an absolute pre-operative value of biomarker abundance, ratio's of pre-operative to post-operative biomarker abundance, or ratio values for pairs of certain biomarkers within the subset. Typically, cytokine abundance is expressed in terms of mRNA copy number wherein the copy numbers are ideally normalised to a house keeping gene and quantification of mRNA copy number is determined by RT-PCR containing reference serial dilutions of cytokine specific cDNA.

A disposable safety syringe designed to prevent syringe handlers from being pricked by a needle by covering the needle with a needle shield, is provided. Special attention should be given to syringe needles because they are sharp enough to cause needle stick injuries before and after use. In particular, if a user is accidentally injured by a blood-stained needle, serious infections might be caused through the needle. Accordingly, the needle is covered with the needle shield after use. The needle shield is fitted over a syringe cylinder. A stopping tab prevents the needle shield from sliding off the cylinder. Inserting tabs are formed by cutting part of shield walls, and locking grooves are formed in the end of the inserting tabs. A fixing adapter has an engagement sill formed in the inner side thereof and a number of elastic fins in the outer side thereof, which is fitted on the locking tab of the needle fixer.

The invention provides a preparation method of porcine circovirus type II recombinant lactobacillus plantarum. The preparation method comprises following steps: separated Cap sequence is connected with expression vector pPSCPSP so as to construct expression plasmid pPSCPSP-Cap; expression plasmid pPSCPSP-Cap is inserted into lactobacillus plantarum LP-1 so as to obtain porcine circovirus recombinant lactobacillus plantarum pPSCPSP-Cap-LP-1; a cultured product of pPSCPSP-Cap-LP-1 can be applied directly as an oral vaccine to stimulate bodies to generate antibodies effectively, and reduce the morbidity of porcine circovirus type II obviously. Application of the oral vaccine is beneficial for avoiding of retarded growth, emaciation, sow reproduction disorder, dyspnea, occasionally induced jaundice, diarrhea, extensive pathological changes of visceral organs and skin caused by serious infection of porcine circovirus in livestock breeding, improving of pig herd immunity and health conditions, and increasing of the economic benefit of breeding.

A device for calculating risk of a patient developing a serious infection, the device comprising: a controller; storage storing electronic program instructions for controlling the controller; a display for displaying a user interface; and input means; wherein the controller is operable, under control of the electronic program instructions, to: receive input via the input means, the input comprising one or more values representing respective measures of one or more risk factors associated with biological sample(s) obtained from the patient; process the input to calculate the risk; and display an indication of the calculated risk via the display.